If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Webpackaging logo

    Aptar Pharma to Unveil Inhalation Drug Delivery Solutions at CPhI China 2018

    Quick Contact
    • Aptar Pharma
    Aptar Pharma to Unveil Inhalation Drug Delivery Solutions at CPhI China 2018
    Asia, East Asia, China, Beauty, Personal Care, Personal Care, Eye Care, Health, Pharmaceuticals, Primary Packaging, Airless Packs, Drug Delivery Devices, Formulations, Shows, Associations, Media, Packaging Trade Shows, Events, CPHI

    Aptar Pharma, a leading drug delivery systems provider, is pleased to be exhibiting once again at CPhI China 2018, taking place from June 20-22 at the Shanghai New International Exhibition Center, Shanghai, China.

    At Booth No. N5F30, Aptar Pharma will be introducing new market innovations in inhalation drug delivery for the Chinese market, demonstrating the benefits of these exciting respiratory solutions designed to combat the effects of air pollution.

    They will also be showcasing their innovative Connected Device portfolio, which covers application fields such as Respiratory and Eye Care. Visitors will have the opportunity to discover these intuitive devices featuring fully-connected functionality and software integration for improving patient health outcomes.

    Another highlight of the booth will be Aptar Pharma’s drug delivery systems expertise in dermal innovation. Specialists will be on hand to discuss the newly enhanced dispensing solutions for Aptar Pharma’s Airless Dermal Drug Delivery Systems, providing insight into how their technologies and features can support pharmaceutical professionals’ drug formulations and consumer products.

    In addition to exhibiting, Aptar Pharma is proud to be hosting a half day seminar on Friday morning, June 22, featuring two Aptar Pharma experts who will present the following interactive sessions:

    • ‘Healthy Nose, Healthy Life: A Glance at Global Successful Products for Upper Respiratory Health’ with Guenter Nadler, Director Business Development, Consumer Health Care Division from 9.30-10.30am
    • ‘Say No to Preservatives: Package Innovation for Ophthalmic & Dermal Products’ with Tianjiao Fu, Business Development Manager China, Pharma Sales from 10.30-11.10am

    A Q&A session will follow the seminar, which will take place at location N8 in Meeting Room D from 9.30am to 12.00pm.

    Guenter Nadler of Aptar Pharma, comments, ‘We are delighted to once again participate in CPhI China, which connects us with the entire Chinese pharmaceutical market. We look forward to showcasing our new market innovations and demonstrating our expertise to industry leaders through our broad drug delivery solutions and our seminar presentations at this event’.

    CPhI China is Asia’s leading trade and networking platform covering the entire pharma industry chain and welcomes over 40,000 experts from over 120 countries to network and collaborate on the forthcoming trends for China’s pharma market.

     

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Company News
    • English
    • Modified 24 May 2018
    • Hits 903
    Webpackaging
    Neville and More
    Conzept International